Northland Capmk Forecasts Increased Earnings for BrainsWay

BrainsWay Ltd. (NASDAQ:BWAY) – Equities research analysts at Northland Capmk raised their Q4 2024 EPS estimates for BrainsWay in a report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.02 per share for the quarter, up from their prior forecast of $0.01. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

Other research analysts also recently issued reports about the stock. Northland Securities boosted their target price on shares of BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research report on Thursday, October 3rd. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Monday, October 21st.

BrainsWay Trading Down 4.3 %

BWAY opened at $9.12 on Friday. BrainsWay has a 12-month low of $4.30 and a 12-month high of $10.98. The firm has a 50 day moving average of $9.27 and a two-hundred day moving average of $7.49. The firm has a market capitalization of $152.12 million, a PE ratio of 91.21 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. During the same quarter in the previous year, the firm earned ($0.01) earnings per share.

Institutional Trading of BrainsWay

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in BrainsWay in the first quarter valued at approximately $60,000. Rhumbline Advisers raised its stake in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after acquiring an additional 1,695 shares in the last quarter. Perritt Capital Management Inc acquired a new position in BrainsWay during the 2nd quarter worth $121,000. Good Life Advisors LLC increased its holdings in BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of BrainsWay by 583.2% in the 1st quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock valued at $923,000 after buying an additional 149,740 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.